Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.
Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, Gueye M, Liégeois F, Kane CT, Butel C, Mbuagbaw J, Zekeng L, Mboup S, Mpoudi-Ngolé E, Peeters M, Delaporte E. Laurent C, et al. Among authors: zekeng l. J Infect Dis. 2002 Aug 15;186(4):486-92. doi: 10.1086/341833. Epub 2002 Jul 19. J Infect Dis. 2002. PMID: 12195375
Antiretroviral drug resistance and routine therapy, Cameroon.
Laurent C, Kouanfack C, Vergne L, Tardy M, Zekeng L, Noumsi N, Butel C, Bourgeois A, Mpoudi-Ngolé E, Koulla-Shiro S, Peeters M, Delaporte E. Laurent C, et al. Among authors: zekeng l. Emerg Infect Dis. 2006 Jun;12(6):1001-4. doi: 10.3201/eid1206.050860. Emerg Infect Dis. 2006. PMID: 16707062 Free PMC article.
Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage.
Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F, Laurent C, Butel C, Zekeng L, Delaporte E, Peeters M. Vergne L, et al. Among authors: zekeng l. Virology. 2003 Jun 5;310(2):254-66. doi: 10.1016/s0042-6822(03)00167-3. Virology. 2003. PMID: 12781713 Free article.
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E. Laurent C, et al. Among authors: zekeng l. Lancet. 2004 Jul 3-9;364(9428):29-34. doi: 10.1016/S0140-6736(04)16586-0. Lancet. 2004. PMID: 15234853 Clinical Trial.
T lymphocyte subset values among healthy Cameroonians.
Zekeng L, Sadjo A, Meli J, Kaptué L, Mpoudi Ngole E, Hess G, Babiel R. Zekeng L, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jan 1;14(1):82-3. doi: 10.1097/00042560-199701010-00016. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 8989218 No abstract available.
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detection.
Ondoa P, Willems B, Fransen K, Nkengasong J, Janssens W, Heyndrickx L, Zekeng L, Ndumbe P, Simon F, Saragosti S, Gürtler L, Peeters M, Korber B, Goudsmit J, van der Groen G. Ondoa P, et al. Among authors: zekeng l. AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):963-72. doi: 10.1089/aid.1998.14.963. AIDS Res Hum Retroviruses. 1998. PMID: 9686642
106 results